← All indications
Hip Fractures
Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
Subtype terms (1)
More specific conditions that are subtypes of Hip Fractures in the MeSH hierarchy.
- Femoral Neck Fractures
20 drugs (18 approved, 2 experimental)
Drugs by status
Phase 4 trials (41)
- diclofenac
- ferric derisomaltose
- propofol
- vitamin d3
- iron
- urea
- bisacodyl
- cetearyl alcohol
- norepinephrine
- ibuprofen
- ferric carboxymaltose
- sevoflurane
- hydroxymethylbutyrate
- iron dextran
- levosimendan
- metamizole
- naproxen
- flumazenil
- ropivacaine
- acetaminophen
- lidocaine
- epinephrine
- red blood cells
- remimazolam
- rocuronium
- levobupivacaine
- bupivacaine
- tramadol
- zoledronic acid
- zolpidem
- +11 more
Phase 3 trials (14)
Phase 2 trials (11)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (57)
- Abbott
- Merck
- Eli Lilly
- Corporacion Parc Tauli
- Hamilton Health Sciences Corporation
- Fundacio Salut i Envelliment UAB
- ZonMw: The Netherlands Organisation for Health Research and Development
- Landstinget i Värmland
- Aarhus University
- Rockefeller University
- Consorci Sanitari de Terrassa
- Cukurova University
- Good Samaritan Regional Medical Center, Oregon
- Hacettepe University
- Harbin Medical University
- Maimonides Medical Center
- Loyola University
- McMaster University
- Pontificia Universidad Catolica de Chile
- ProMedica Health System
- Shanxi Medical University
- Sykehuset i Vestfold HF
- University of Kentucky
- University of Saskatchewan
- University of Southern Denmark
- Yale University
- University of Valencia
- Mayo Clinic
- Fudan University
- Peking University
- +27 more
Organization Involved with Phase 3 Indications (45)
- Daiichi Sankyo
- Fresenius
- Astellas
- Sanofi
- Novartis
- Eurofarma Laboratorios S.A.
- GlaxoSmithKline
- Pluristem Ltd.
- Solvay
- Gamida Cell
- Fundación Pública Andaluza
- Swiss National Science Foundation
- University of Pennsylvania
- Medical University of Graz
- Baskent University
- Bronovo Hospital
- Chulalongkorn University
- Harvard University
- Johns Hopkins University
- Lancaster General Hospital
- McGill University
- Sanquin
- Triemli Hospital
- University of Maryland
- University of Seville
- Utrecht University
- University of Alberta
- University of Zurich
- Peterborough and Stamford Hospitals NHS Foundation Trust
- University of Colorado, Denver
- +15 more
Organization Involved with Phase 2 Indications (20)
- Azelon Pharmaceuticals
- Viking Therapeutics, Inc.
- vTv Therapeutics
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute on Aging (NIA)
- University of London
- Cornell University
- Helen Hayes Hospital
- Hoosier Cancer Research Network
- Lenox Hill Hospital
- Rhode Island Hospital
- RWTH Aachen University
- University of Adelaide
- University of Athens
- Optum
- University of Gothenburg
- Amager Hospital
- Government of Denmark
- Air Liquide
- New York Hospital Queens
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (21)
- National Institutes of Health (NIH)
- Centro Hospitalar do Porto
- Changi General Hospital
- KAT General Hospital
- Lithuanian University of Health Sciences
- Lund University
- Medical University of Warsaw
- Thomas Jefferson University
- University of Rochester
- University of Rostock
- University of Thessaly
- Zagazig University
- Tel Aviv University
- Virginia Polytechnic Institute and State University
- Emek Medical Center
- University of Porto
- Asklepieion General Hospital
- Kassab Institute of Orthopedics
- Karolinska Institute
- Aretaieion University
- Noordwest Ziekenhuisgroep